Scilex Holding CO 8-K filings

Scilex Holding Company has entered into an uncommitted revolving line of credit agreement with Vivasor, Inc. for up to $20 million, with funding subject to Scilex's sole discretion.

Scilex Holding Company has entered into a stock repurchase agreement with Vivasor Holding Company to sell previously acquired preferred stock for approximately $12 million, with payments structured in tranches through June 2027.

Scilex Holding Company has signed a binding term sheet with iHolding Group LLP for a proposed $100 million investment in newly issued common stock.

Scilex Holding Company has entered into a binding term sheet to purchase 837 Bitcoin for $50 million from Datavault AI Inc., with an initial payment of $30 million.

Scilex Holding Company stockholders elected a director, ratified auditors, and approved an increase in equity incentive plan shares at the 2026 Annual Meeting.

Scilex Holding Company details the distribution of Dream Bowl Meme Coin I tokens as a dividend to eligible equity holders, outlining the process, record date, and payment date.

Scilex Holding Company's subsidiary, ACEA Therapeutics, Inc., has entered into a definitive agreement to sell 100% of ACEA Pharma, Inc. to Phoenix Asia Holdings Limited for $1 billion in newly-issued Phoenix Asia ordinary shares.

Scilex Holding Company has entered a binding term sheet to invest $120 million in Datavault AI for a revenue-sharing infrastructure partnership.

Scilex Holding Company has filed a federal lawsuit seeking over $100 million in damages and recovery of 96 million shares, alleging unauthorized sale of collateral securities by multiple defendants including BNY Mellon.

Scilex Holding Company has filed a lawsuit against Marc Wade, St. James Bank & Trust, Omega & Corinth Group, and Bank of New York Mellon Corporation, alleging securities fraud, fraudulent inducement, conversion, and negligence related to a non-recourse loan and the unauthorized sale of over 85 million Datavault AI shares.

Scilex Holding Company's Board of Directors has revoked a previously declared stock dividend of Series 1 Mandatory Exchangeable Preferred Stock, eliminating the designation.

Scilex Holding Company announced a $20 million convertible note and a $27.5 million stock purchase, acquiring a substantial equity stake in Quantum Scan Holdings, Inc.

Scilex Holding Company announced the full exercise of its option to repurchase 6.5 million Penny Warrants from Oramed Pharmaceuticals for an aggregate of $27 million.

Scilex Holding Company announced the closing of the first tranche of its previously disclosed non-recourse loan, securing approximately $22.6 million.

Scilex Holding Company's wholly-owned subsidiary, SCLX Stock Acquisition JV LLC, has entered into a non-recourse loan agreement for up to $100 million, secured by a pledge of Scilex common stock.

Scilex Holding Company amended its non-recourse loan agreement, increasing the available principal to $100 million and pledging an additional 46.6 million shares of Datavault AI Inc. common stock.

Scilex Holding Company stockholders approved a one-time repricing of certain outstanding stock options, significantly reducing their exercise price to $16.80 per share.

Scilex Holding Company has entered into a non-recourse loan agreement for up to $50 million, secured by a pledge of approximately 39.2 million shares of Datavault AI Inc. common stock.

Scilex Holding Company finalized its strategic investment in Datavault AI Inc., acquiring a significant equity stake for $150 million in Bitcoin.

Scilex Holding Company entered into an agreement with an institutional investor to exercise existing warrants for $20.3 million, issuing new warrants and reducing exercise prices.

Scilex Holding Company has entered into a worldwide exclusive license agreement with Datavault AI Inc. to develop a Biotech Exchange platform for tokenizing and monetizing genomic and drug data.

Scilex Holding Company has terminated its equity line of credit agreement with Tumim Stone Capital, LLC, agreeing to pay $2.7 million in cash instead of issuing 150,000 shares.

Scilex Holding Company announced the appointment of Stephen Ma, previously CFO, as its new Chief Operating Officer, effective October 1, 2025.

Scilex Holding Company secured approximately $2.7 million by exercising existing warrants and deferring a debt payment, issuing new warrants to investors.

Scilex Holding Company announced a $150 million strategic investment in Datavault AI Inc., utilizing Bitcoin to acquire common stock and warrants, aiming to capitalize on the biotech data monetization market.

Scilex Holding Company has sold 12.5 million shares of its majority-owned subsidiary, Semnur Pharmaceuticals, for $200 million, receiving payment in Bitcoin.

Scilex Holding Company announced director resignations, a board size reduction, and the appointment of CFO Stephen Ma to the board, alongside a five-year consulting agreement with former director Jaisim Shah's affiliate.

Scilex Holding Company announces its CEO, Jaisim Shah, will now lead its subsidiary Semnur Pharmaceuticals full-time, alongside a new $20 million private placement for Semnur's SP-102 development, with Henry Ji, Ph.D., appointed as Scilex's new CEO.

Scilex Holding Company's subsidiary, Semnur Pharmaceuticals, Inc., has amended its merger agreement with Denali Capital Acquisition Corp. to allow for the issuance of additional shares for potential private placement financing and service provider compensation prior to the business combination.

Scilex Holding Company has entered into a new $100 million equity line of credit, exchanged existing Tranche B warrants for new ones with adjusted terms, and agreed to repurchase 6.5 million low-exercise price warrants from Oramed Pharmaceuticals Inc.